The world's first drug RPL554 was used for COPD maintenance treatment phase 2 trials with positive results
March 28, 2018 Source: Sina Pharmaceutical
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];On March 26, Verona Pharma, a biopharmaceutical company focused on the development of innovative therapeutics for respiratory diseases in the UK, announced that the company's drug candidate RPL554 is used in the treatment of chronic obstructive pulmonary disease (COPD) for the treatment of active clinical stage 2b top line data, RPL554 It is the world's first phosphodiesterase 3 and 4 inhibitor with dual effects of bronchiectasis and anti-inflammatory.
This 4-week, double-blind, placebo-controlled, phase 2b European multicenter study in an outpatient setting evaluated the efficacy and safety of twice daily RPL554 spray for maintenance of 403 patients with moderate to severe COPD. And dose response. In addition to placebo, there were four RPL 554 dosing cohorts (0.75 mg, 1.5 mg, 3.0 mg, and 6.0 mg) and patients had to discontinue treatment with conventional long-acting bronchodilators during the study.
Primary endpoint:
· All doses of RPL554 reached the primary endpoint. Compared with placebo, RPL554 achieved a clinically and statistically significant improvement (p < 0.001) in 1 second maximum expiratory volume (FEV 1) in patients with moderate to severe COPD over a 4 week period.
· The peak of FEV 1 was significantly improved at all time points around the administration period.
· After 4 weeks of dosing, the FEV 1 peak has an absolute change of >200 ml. The minimum effective dose cannot be determined.
· The strongest bronchodilation effect was observed during the first dose and lasted for more than 4 weeks (p < 0.001).
Secondary end point:
· After the first dose, the mean FEV 1 of all doses improved significantly within 12 hours, and this effect lasted for more than four weeks.
· This study did not confirm a consistent improvement in the FEV1 trough.
· E-RS (EXACT-PRO) was used to record daily symptoms of chronic obstructive pulmonary disease, showing a significant improvement in the overall symptoms of chronic obstructive pulmonary disease (p < 0.002), including dyspnea (p < 0.0 2), Chest symptoms (p < 0.0 2), cough and multiple sputum (p < 0.0 2).
· After 4 weeks, a significant improvement in SGRQ-C2 >2.5 units was observed in each dose group.
· The Patient Total Impression Change Scale showed that patients with RPL554 felt better (p<0.01) compared with placebo.
· RPL 554 is well tolerated at all doses and adverse events occur similarly to placebo.
Dr. Dave Singh, a professor of clinical pharmacology and respiratory medicine at the University of Manchester's Drug Evaluation Department and a principal investigator of the study, said: "This relatively large and well-designed study is encouraging and clinically meaningful. It is worth noting that the study observed a significant sustained improvement in lung function and a reduction in symptoms of chronic obstructive pulmonary disease, including a reduction in dyspnea. These data, combined with the unique mechanism of action of the drug, highlight RPL 554 as a new complementary therapy. The potential for this disease is still high unmet medical needs."
Dr. Ken Newman, Chief Medical Officer of Verona Pharma, said: "I am pleased to study the primary endpoint of FEV 1 peak, confirming the strong bronchodilation effect of RPL 554 in patients with COPD. The daily reported chronic obstructive pulmonary disease symptom score is clinically Significant improvements and continuous improvement during the four-week treatment period."
Verona CEO Jan-Anders Karlsson said: "These results provide strong support for RPL 554 as a late-stage clinical study of inhalation therapy for patients with COPD. Future clinical development and positioning of this new therapy will be based on this data and this year. The results will be clear as a result of complementary treatments for combination therapies, and we are conducting market research and market positioning."
In previous clinical trials, bronchodilation effects have been observed when RPL554 is used alone or as a supplement to other COPD bronchodilators. In addition to the usual short-acting and long-acting bronchodilators (eg, tiotropium), concurrent administration of RPL554 also showed clinically significant and statistically significant improvement in lung function. In addition, RPL 554 showed an anti-inflammatory effect in a standard challenge study on COPD-like inflammation. RPL 554 has good safety and tolerability and has been used in more than 730 subjects in 12 clinical trials. (Sina Pharmaceutical Compilation / David)
Article Reference Source: Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
Automatic Massage Collapsible Foot Spa Massager
Auto Massage Foldable Foot Spa Massager is a device that provides relaxing and rejuvenating foot massage. It has a collapsible design for easy storage and transport. The massager has multiple massage rollers that target specific pressure points on your feet to deliver a deep tissue massage that helps relieve tension and improve circulation. It also has a heating function that can help soothe sore muscles and promote relaxation. The massager is easy to use and can be controlled with the push of a button. It's a great way to pamper yourself after a long day on your feet or to relieve foot pain and discomfort.
Automatic Massage Collapsible Foot Spa Massager,Folding Foot Bath Machine,Foot Spa,Massager Folding Foot Spa
Huaian Mimir Electric Appliance Co., LTD , https://www.mimirfootbath.com